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Background: In the PALOMA-3 study, palbociclib plus fulvestrant demonstrated improved progression-free survival
compared with fulvestrant plus placebo in hormone receptor-positive, HER2− endocrine-resistant metastatic breast
cancer (MBC). This analysis compared patient-reported outcomes (PROs) between the two treatment groups.
Patients and methods: Patients were randomized 2 : 1 to receive palbociclib 125 mg/day orally for 3 weeks followed by 1
week off (n= 347) plus fulvestrant (500 mg i.m. per standard of care) or placebo plus fulvestrant (n = 174). PROs were
assessed on day 1 of cycles 1–4 and of every other subsequent cycle starting with cycle 6 using the EORTC QLQ-C30 and its
breast cancer module, QLQ-BR23. High scores (range 0–100) could indicate better functioning/quality of life (QoL) or worse
symptom severity. Repeated-measures mixed-effect analyses were carried out to compare on-treatment overall scores and
changes from baseline between treatment groups while controlling for baseline. Between-group comparisons of time to deteri-
oration in global QoL and pain were made using an unstratiﬁed log-rank test and Cox proportional hazards model.
Results: Questionnaire completion rates were high at baseline and during treatment (from baseline to cycle 14, ≥95.8% in
each group completed ≥1 question on the EORTC QLQ-C30). On treatment, estimated overall global QoL scores signiﬁcantly
favored the palbociclib plus fulvestrant group [66.1, 95% conﬁdence interval (CI) 64.5–67.7 versus 63.0, 95% CI 60.6–65.3;
P= 0.0313]. Signiﬁcantly greater improvement from baseline in pain was also observed in this group (−3.3, 95% CI −5.1 to
−1.5 versus 2.0, 95% CI −0.6 to 4.6; P = 0.0011). No signiﬁcant differences were observed for other QLQ-BR23 functioning
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domains, breast or arm symptoms. Treatment with palbociclib plus fulvestrant signiﬁcantly delayed deterioration in global QoL
(P< 0.025) and pain (P < 0.001) compared with fulvestrant alone.
Conclusion: Palbociclib plus fulvestrant allowed patients to maintain good QoL in the endocrine resistance setting while ex-
periencing substantially delayed disease progression.
Clinical Trial Registration:NCT01942135.
Key words: endocrine resistance, palbociclib, patient-reported outcomes, breast cancer, quality of life
introduction
Palbociclib (Ibrance®, Pﬁzer, New York, NY) is an orally bio-
available small-molecule inhibitor of cyclin-dependent kinases
(CDKs) with a high level of selectivity for CDK4 and CDK6
versus other CDKs [1]. In preclinical studies, palbociclib is
highly active in hormone receptor-positive (HR+) breast cancer
cell lines and is synergistic with endocrine therapies [2]. In a
randomized phase II study (PALOMA-1) of patients with estro-
gen receptor-positive (ER+), human epidermal growth factor re-
ceptor 2-negative (HER2−) metastatic breast cancer (MBC),
palbociclib in combination with letrozole resulted in improved
progression-free survival (PFS) that was nearly double that of
patients receiving letrozole alone [3]. Because deregulation of
CDK4/CDK6 has been implicated in endocrine resistance, pal-
bociclib was investigated in the phase III PALOMA-3 study
comparing palbociclib plus fulvestrant with placebo plus fulves-
trant in patients with endocrine-resistant, HR+, HER2− advanced
breast cancer. The recently reported primary results demon-
strated a signiﬁcant improvement in PFS with palbociclib plus
fulvestrant [median 9.2 versus 3.8 months; hazard ratio (HR):
0.42; 95% conﬁdence interval (CI) 0.32–0.56; P < 0.001] [4].
The major clinical challenge of managing HR+, HER2−MBC
is that most patients eventually develop resistance to endocrine
therapy. Delaying disease progression, even in the absence of an
overall survival beneﬁt, may help maintain quality of life (QoL) on
treatment at levels that are higher than what would be experienced
with disease progression. Yet, addition of novel treatments to exist-
ing ones can add toxicities, which could diminish patients’ QoL [5,
6]. Therefore, maintaining QoL is particularly relevant in the endo-
crine resistance setting, for which there are several treatment
options including either a combination of endocrine therapy with
a targeted agent (e.g. phosphoinositide 3-kinase or mammalian tar-
get of rapamycin inhibitors) or a switch to chemotherapy. Previous
studies have shown worse QoL with chemotherapy versus endo-
crine therapy [7]. A novel agent that would enhance endocrine
therapy activity and still maintain adequate QoL is clinically
desired. Hence, when evaluating new treatments (especially com-
bination regimens), it is important to evaluate the quality of the
time gained by delaying disease progression via patient-reported
outcomes (PROs) as an integral component of beneﬁt-risk assess-
ments. Previously, we reported top-level results of the impact of
palbociclib therapy on global QoL and emotional functioning [4].
Here, we report the detailed PROs results from PALOMA-3.
methods
trial design and participants
PALOMA-3 was an international, multicenter, ongoing double-blind, paral-
lel-group phase III study in which patients were randomized 2 : 1 to receive
palbociclib plus fulvestrant or matching placebo plus fulvestrant, respective-
ly. The primary objective was to demonstrate the superiority of palbociclib
plus fulvestrant over placebo plus fulvestrant in prolonging investigator-
assessed PFS in women with HR+, HER2− MBC whose disease had pro-
gressed after prior endocrine therapy.
randomization and study treatments
Randomization was stratiﬁed by documented sensitivity to prior hormonal
therapy (yes versus no), menopausal status (pre/peri- versus postmenopau-
sal), and presence of visceral metastases (yes versus no). Palbociclib/placebo
was orally administered daily on days 1–21, followed by 7 days off-treatment
of every 28-day cycle. In cycle 1, fulvestrant was administered intramuscular-
ly on days 1 and 15, every 28 ± 7 days thereafter starting on day 1 of cycle
2. All pre-/perimenopausal women received goserelin for the duration of
study treatment. The study was stopped early at the planned interim analyses
for PFS. A detailed study design was previously reported [4].
PRO assessment
The PROs were assessed using the European Organisation for Research and
Treatment of Cancer Quality-of-Life questionnaire (EORTC QLQ-C30 v3.0)
and its breast cancer module (EORTC QLQ-BR23). Patients completed
these instruments on day 1 of cycles 1–4, then on day 1 of every other subse-
quent cycle starting with cycle 6 (e.g. cycles 6, 8, 10, etc.), and at the end-of-
treatment visit. Patients were to complete these instruments in the clinic
before any tests and/or discussions of their progress with health care person-
nel at the site. The completed questionnaires were considered source docu-
ments and ﬁled accordingly.
The EORTC QLQ-C30 is a 30-item questionnaire composed of a global
QoL subscale, 5 multi-item functional subscales (physical, role, emotional,
cognitive, and social functioning), 3 multi-item symptom scales (fatigue,
nausea/vomiting, and pain), and 5 single-item symptom scales assessing other
cancer-related symptoms (dyspnea, sleep disturbance, appetite loss, constipa-
tion, and diarrhea). The questionnaire consists of 4-point Likert scale items
with responses from ‘not at all’ to ‘very much’ to assess functioning and symp-
toms and two 7-point Likert scale items for global health and overall QoL [8].
The EORTC QLQ-BR23 is a 23-item breast cancer-speciﬁc companion
module to the EORTC QLQ-C30 and consists of four functional scales (body
image, sexual functioning, sexual enjoyment, future perspective) and four
symptom scales (systemic side-effects, breast symptoms, arm symptoms, upset
by hair loss). Responses to all items were converted to a 0–100 scale using a
standard scoring algorithm [9]. For functional and global QoL scales, higher
scores represent a better level of functioning/QoL than lower scores; for
symptom-oriented scales, higher scores represent greater symptom severity.
For the single items, if two answers were given to a single question, the more
severe answer was counted. If ≥50% of the questions were answered for the
multi-item scales, the scale score was the mean score. If <50% of the questions
in any scale were answered, the score was considered missing.
statistical analysis
All PRO analyses were based on the PRO-evaluable population (i.e. patients
in the intent-to-treat population with a baseline and ≥1 postbaseline
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assessment before the end of study treatment). Completion rates were sum-
marized by cycle. The primary PRO analysis prespeciﬁed for comparing the
two treatment groups was a longitudinal analysis based on a longitudinal
mixed-effect random intercept random slope model. Treatment, time, treat-
ment by time, and baseline were covariates for the model. A restricted
maximum likelihood method assuming an unstructured covariance matrix
was used. This analysis was carried out based on both the observed values
and the changes from baseline for EORTC QLQ-C30 and QLQ-BR23 scales.
Analysis of time to deterioration (TTD) in pain scores was prespeciﬁed; de-
terioration was deﬁned as an increase of ≥10 points from baseline.
Post hoc analyses of TTD in global QoL were carried out using survival
analysis methods. Deterioration was deﬁned as a decrease of ≥10 points
from baseline, with no subsequent increase above this threshold. The 10-
point threshold was chosen based on previously established thresholds for
minimal important differences from the perspective of the patient [10].
Patients not meeting deterioration criteria were censored at treatment dis-
continuation or death (whichever occurred earlier) or time of last available
PRO assessment if the patient was alive and continuing treatment. Survival
analysis methods included the Kaplan–Meier approach for estimating
medians and percentiles, the Brookmeyer and Crawley method for comput-
ing 95% CIs, assuming proportional hazards for computing HR, and using
the log-rank test (one-sided; α = 0.025) in comparing TTD between the two
treatment groups. A repeated-measures model for the subgroup of patients
with visceral metastases at baseline was also performed. No adjustments
were made for multiple comparisons. All analyses were conducted using
Statistical Analysis System software (SAS Institute, Cary, NC) for Windows
(Microsoft Corp., Redmond, WA). All P values are two-sided unless stated
otherwise.
results
Of 521 patients, 347 were randomized to the palbociclib plus
fulvestrant group and 174 to the placebo plus fulvestrant group.
Two (0.6% and 1.1%, respectively) patients in each group were
randomized but not treated. Baseline characteristics were well
balanced across treatment groups (see supplementary Table S1,
available at Annals of Oncology online). Median age was 57
years. The majority of patients had visceral metastases (palboci-
clib plus fulvestrant, 59.4%; placebo plus fulvestrant, 60.3%; see
supplementary Table S1, available at Annals of Oncology
online). Most patients had ≥2 lines of treatment in the metastat-
ic setting and over one-third had ≥3 disease sites involved. One-
third of patients received chemotherapy in the advanced setting
(30.8% versus 36.2%).
From baseline to cycle 14, ≥96.9% of patients in the palboci-
clib plus fulvestrant group and ≥95.8% in the placebo plus ful-
vestrant group, respectively, completed ≥1 question on the
EORTC QLQ-C30 (see supplementary Table S2, available at
Annals of Oncology online); ≥93.8% and ≥95.8% completed ≥1
question on the EORTC QLQ-BR23.
global QoL
Baseline mean (95% CI) scores for global QoL were similar for
the palbociclib plus fulvestrant and placebo plus fulvestrant
groups [65.9 (63.5–68.2) versus 65.3 (61.9–68.6)]. Baseline scores
in the study were within range of reference values published pre-
viously [11] in recurrent/MBC patients (Table 1). As shown in
Figure 1, the repeated-measures mixed-effect model estimated a
signiﬁcant between-group difference in overall change from base-
line score for global QoL, which has been reported previously [4].
The difference between treatment groups in estimated overall
global QoL scores was found to be statistically signiﬁcant favoring
palbociclib plus fulvestrant [66.1 (95% CI: 64.5–67.7) versus 63.0
(95% CI: 60.6–65.3); P = 0.0313]. A signiﬁcantly greater delay in
deterioration of QoL was observed in the palbociclib plus fulves-
trant versus control (median not reached; HR: 0.641; 95% CI:
0.451–0.910; 1-sided P = 0.0065; Figure 2A).
functional scales (QLQ-C30)
Baseline scores for all ﬁve QLQ-C30 functional scales were
similar between groups with high functioning levels in both.
Estimated changes from baseline for the functional scales are
presented in Figure 1. Between-group differences in changes
from baseline scores were signiﬁcant only for emotional func-
tioning [2.7 (95% CI 1.1–4.3) versus −1.9 (95% CI −4.2 to 0.5);
P = 0.0016) and favored palbociclib plus fulvestrant. The overall
change from baseline scores for physical, role, cognitive, and
social functioning was not found to be statistically signiﬁcantly
different between the two treatment groups (Figure 1). Within
each treatment group, changes from baseline indicated signiﬁ-
cant improvement (based on interpretation from the 95% CIs)
with palbociclib plus fulvestrant in emotional functioning. In
contrast, there was signiﬁcant worsening with placebo plus ful-
vestrant in role functioning, signiﬁcant worsening for both
treatment groups in cognitive functioning, and no signiﬁcant
change from baseline for either group in the other functional
scales.
symptom scales (QLQ-C30)
Mean baseline scores for symptoms of the EORTC QLQ-C30
were similar in both treatment groups for all symptoms except
insomnia (26.3 versus 32.9 for palbociclib plus fulvestrant
versus placebo plus fulvestrant). Baseline symptom scores were
on the lower end of the 0–100 score range, indicating low
symptom severity in both groups. Differences between treatment
comparisons for change from baseline scores for the EORTC
QLQ-C30 symptoms are displayed in Figure 3A.
Signiﬁcant decrease from baseline in pain was observed with
palbociclib plus fulvestrant compared with placebo plus fulves-
trant [−3.3 (95% CI −5.1 to −1.5) versus 2.0 (95% CI −0.6 to
4.6); P = 0.0011] and signiﬁcantly less deterioration from baseline
was observed for nausea/vomiting [1.7 (95% CI 0.4–3.0) versus
4.2 (95% CI 2.3–6.1); P = 0.0369]. No signiﬁcant differences
between groups were observed in overall change from baseline
scores for any other EORTC QLQ-C30 symptoms (Figure 3A).
The estimated median TTD in pain was 8 months (95% CI
5.6–not estimable) in the palbociclib plus fulvestrant group
compared with 2.8 months (95% CI 2.3–5.4) in the placebo
plus fulvestrant group. Treatment with palbociclib plus fulves-
trant signiﬁcantly delayed TTD in pain symptoms versus
placebo plus fulvestrant [HR, 0.642 (95% CI 0.487–0.846);
P < 0.001; Figure 2B].
functional scales (QLQ-BR23)
Mean baseline scores of the functional scales body image, sexual
functioning, sexual enjoyment, and future perspective were
generally similar in both treatment groups. However, the sample
sizes for sexual enjoyment are smaller versus other scales
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because patients were asked to respond to this question only if
they responded that they were sexually active in a previous ques-
tion. Between-group differences in changes from baseline QLQ-
BR23 functional scale scores are displayed in Figure 3B. No
signiﬁcant difference was observed between treatment groups in
overall change from baseline scores for any of the breast cancer-
speciﬁc functional scales. Based on interpretation from the 95%
CIs of the overall change from baseline analysis within each
treatment group, signiﬁcant improvement in body image and
future perspective was observed in the palbociclib group; signiﬁ-
cant deterioration in sexual enjoyment was observed in both
groups.
symptom scales (QLQ-BR23)
Because the question on hair loss was addressed only to patients
who experienced hair loss, sample sizes for the symptom scale
‘upset by hair loss’ are much lower than those for other scales.
Hair loss was reported in 14.8% versus 5.8% of patients per
Common Terminology Criteria for Adverse Events version 4.0.
Nearly all events were grade 1 (hair thinning); 1.2% of patients
receiving palbociclib plus fulvestrant and no patients receiving
placebo plus fulvestrant reported grade 2 (complete hair loss).
The between-treatment comparison in overall change from
baseline QLQ-BR23 symptom scale scores are displayed in
Figure 3C. Signiﬁcantly greater deterioration from baseline was
observed with palbociclib for upset by hair loss [2.9 (95% CI
−1.7 to 7.4) versus −6.0 (95% CI −12.3 to 0.3); P = 0.0255]. No
signiﬁcant between-treatment difference was observed in any of
the other breast cancer-speciﬁc symptoms. The overall changes
within each group, based on interpretation from the 95% CIs of
the change from baseline analysis (not adjusted for multiple
comparisons), indicate a signiﬁcant improvement in breast
symptoms in the palbociclib group, a signiﬁcant improvement
in arm symptoms in both groups, and a signiﬁcant worsening of
systemic therapy side-effects in both groups.
The subgroup analyses results for patients with visceral me-
tastases at baseline (palbociclib plus fulvestrant, n = 199;
placebo plus fulvestrant, n = 101) were consistent with the
primary analyses in the overall population and showed a sig-
niﬁcant difference between the treatment groups favoring pal-
bociclib plus fulvestrant in global QoL, emotional functioning,
Table 1. Baseline scores for EORTC QLQ-C30 and BR-23 scales and reference values (PRO analysis set)
Domain/scale Palbociclib + fulvestrant (N = 335) Placebo + fulvestrant (N = 166) Reference values [11]a
nb Mean (95% CI) nb Mean (95% CI) Mean (SD)
EORTC QLQ-C30 Global QoL and Functional Scales
Global QOL 334 65.9 (63.5–68.2) 166 65.3 (61.9–68.6) 60.2 (25.5)
Physical functioning 334 79.4 (77.3–81.5) 166 78.9 (76.1–81.7) 81.6 (18.7)
Role functioning 333 78.5 (75.7–81.2) 166 77.6 (73.8–81.5) 67.4 (31.1)
Emotional functioning 334 74.6 (72.4–76.8) 166 72.8 (69.7–76.0) 65.9 (24.6)
Cognitive functioning 334 84.8 (82.8–86.8) 166 82.1 (79.2–85.1) 80.5 (23.2)
Social functioning 334 81.3 (78.7–83.9) 166 78.5 (74.7–82.4) 74.2 (28.4)
EORTC QLQ-C30 Symptoms
Fatigue 334 32.1 (29.7–34.5) 166 32.2 (28.9–35.5) 36.3 (27.0)
Nausea/vomiting 335 7.4 (5.6–9.1) 166 5.2 (3.4–7.0) 10.3 (19.7)
Pain 335 26.6 (23.9–29.3) 166 27.5 (23.7–31.3) 30.9 (29.6)
Dyspnea 334 15.7 (13.3–18.1) 166 16.5 (13.0–19.9) 20.4 (28.2)
Insomnia 335 26.3 (23.4–29.1) 166 32.9 (28.4–37.5) 33.1 (32.6)
Appetite loss 335 16.8 (14.1–19.5) 166 12.9 (9.4–16.3) 21.7 (31.0)
Constipation 333 13.6 (11.1–16.2) 166 13.7 (10.5–16.8) 19.2 (28.8)
Diarrhea 332 5.4 (3.9–6.9) 166 6.2 (4.1–8.4) 5.8 (15.2)
EORTC QLQ-BR23 Functional
Body image 333 74.8 (71.9–77.7) 164 73.8 (69.4–78.3) 81.9 (22.6)
Sexual functioning 321 16.1 (13.7–18.5) 164 13.9 (10.7–17.1) 19.2 (23.2)
Sexual enjoyment 141 44.9 (39.5–50.0) 64 37 (28.4–45.5) 55.1 (25.6)
Future perspective 333 43.1 (39.7–46.6) 165 43.6 (28.9–48.4) 47.6 (34.1)
EORTC QLQ-BR23 Symptoms
Systemic therapy side-effects 335 15.7 (14.2–17.1) 166 17.1 (15.1–19.1) 15.8 (14.3)
Breast symptoms 330 10.5 (8.7–12.2) 166 11 (8.5–13.5) 17.6 (16.7)
Arm symptoms 334 16 (13.8–18.1) 166 18.1 (14.9–21.3) 21.0 (21.1)
Upset by hair lossc 104 28.5 (22.1–34.9) 55 26.7 (18.5–34.9) 5.3 (19.3)
BR23, Breast Cancer Module; C30, core 30 items; CI, confidence interval; EORTC QLQ, European Organization for Research and Treatment of Cancer
Quality of Life Questionnaire; PRO, patient-reported outcomes; QOL, quality of life; SD, standard deviation.
aReference values for recurrent/metastatic breast cancer patients across all lines of treatment.
bNumber of patients with data available for the corresponding visit.
cOnly patients who experienced hair loss were required to complete this question.
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nausea/vomiting, and pain. In addition, a signiﬁcant difference
between treatment groups was observed for role functioning favor-
ing palbociclib plus fulvestrant.
discussion
Given that treatment for MBC is palliative and not curative in
nature, when introducing new therapies with increased efﬁcacy
it is critical to demonstrate that patient QoL is not compromised
and there is no signiﬁcant deterioration in functioning or symp-
toms compared with the current standard of care. The recently
published European Society for Medical Oncology Magnitude
of Clinical Beneﬁt Scale guidance emphasized the importance of
a holistic assessment of the value of medicine that includes
PROs in addition to efﬁcacy and safety. Presented herein is
detailed information about PROs with palbociclib that, together
with the efﬁcacy data, could assist with this assessment and
argue for high scores for the palbociclib combination on this
scale. We show that the favorable efﬁcacy achieved by addition
of palbociclib to fulvestrant is accompanied by a delay in deteri-
oration of QoL and pain symptoms. Patients maintained good
QoL when an active treatment was added to a well-tolerated
endocrine agent, whereas their QoL deteriorated on the endo-
crine agent alone. No signiﬁcant difference was observed
between the two treatment groups in deterioration of systemic
side-effects, breast symptoms, and arm symptoms.
Based on TTD in global QoL, addition of palbociclib to
endocrine therapy resulted in a 36% reduction in risk of QoL
deterioration. Delayed deterioration in global QoL and pain
symptoms with palbociclib corresponds to the delay in disease
progression that was previously reported [4]. As disease pro-
gression may negatively impact patient QoL, delaying progres-
sion could delay QoL deterioration barring any signiﬁcant
detrimental effect due to treatment-related toxicity. Our results
further support the positive risk-beneﬁt proﬁle of palbociclib
in combination with fulvestrant and show that addition of pal-
bociclib does not impose toxicities that interfere with patient
QoL. Pain has been shown to have a signiﬁcant negative impact
on QoL in advanced/MBC patients [12]. Consequently, redu-
cing or delaying pain symptoms is likely to have a positive
impact on overall patient functioning and QoL.
We analyzed the impact of palbociclib therapy on parameters
considered important by the patients themselves, including
emotional functioning and pain. Emotional functioning is re-
portedly affected by aspects of uncertainty associated with sur-
vival in MBC patients and depression and anxiety have been
reported in MBC patients [13]. Delaying progression in a clinic-
ally meaningful way could potentially decrease the uncertainty
associated with prognosis and survival and have a positive
impact on emotional functioning. However, the differences in
myelosuppression rates between the treatment arms could have
inﬂuenced the patient scoring and may limit the interpretation
of emotional functional scores.
In a recent cross-sectional study by Hollen et al. [14], breast
cancer patients rated maintaining QoL, independence, perform-
ing normal activities, and controlling pain as more important
than control of breast cancer symptoms. Among the symptom
scales examined, signiﬁcantly higher scores in upset by hair loss
were observed among patients reporting hair loss while receiv-
ing palbociclib. This is consistent with the correspondingly
higher rates of alopecia reported in this group (14.8%) versus
the placebo plus fulvestrant group (5.8%).
The observed PROs support the concept that the greater
efﬁcacy and favorable safety proﬁle of palbociclib plus fulves-
trant translates to relatively better QoL compared with placebo
plus fulvestrant. This is demonstrated by a signiﬁcant delay
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Figure 1. Overall change from baseline in EORTC QLQ-C30 scores for global QoL and functional scales in the PRO analysis set. Changes from baseline in the
patient-reported outcomes analysis population were determined using a repeated-measures mixed-effect model. Arrow denotes direction of improved outcome;
changes >0 indicate improvement from baseline. EORTC QLQ-C30, European Organization for Research and Treatment of Cancer Quality of Life
Questionnaire-Core 30 items; PRO, patient-reported outcomes; QoL, quality of life. Asterisks denote that the change from baseline was statistically signiﬁcantly
different between treatment groups.
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Figure 2. Time to deterioration in global QoL (A) and pain (B) in the PRO analysis set. Kaplan–Meier curves of European Organization for Research and
Treatment of Cancer Quality of Life Questionnaire-Core 30 items (EORTC QLQ-C30) scores for the patient-reported outcomes analysis population. CI,
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in deterioration of global QoL and pain symptoms, a signiﬁcant-
ly greater improvement from baseline in emotional functioning
and pain, and no signiﬁcant increase in systemic therapy side-
effects. When palbociclib was added to an already well-tolerated
endocrine agent (fulvestrant), the combination allowed patients
to maintain good QoL in the endocrine resistance setting while
experiencing substantially delayed disease progression.
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